Skip to main content

Cardiovascular Health and Healthy Aging

  • Chapter
  • First Online:
Healthy Aging

Abstract

Cardiovascular disease (CVD) is common in the general population, affecting most individuals over the age of 60. It currently represents over half of all noncommunicable diseases worldwide and is the leading global cause of death, accounting for over 17.3 million deaths per year. The lifetime incidence of CVD is high, as demonstrated by the Framingham Heart Study, where the estimated lifetime risk of developing coronary heart disease (CHD) alone at age 40 was 48.6% for men and 31.7% for women. The demographic shift in aging, coupled with increased survival with CVD, has resulted in an increase in the old and oldest old with chronic CVD-related conditions. Cardiovascular diseases are highly responsible for disability in those ≥ age 75. Coronary heart disease represents approximately one-third to one-half of all CVD cases. There are many lifestyle factors that have contributed to an increasing CVD disease burden, including poor diet, tobacco smoking, elevated body mass index (BMI), hypertension, glucose intolerance, and physical inactivity. Though not a modifiable risk factor, age alone outranks hyperlipidemia, hypertension, and smoking as a clinical predictor of CVD events and is the strongest determinant of heart disease and stroke in several risk factor algorithms. As such, older adults experience the greatest burden of CVD. Although occult CVD and CVD-related events increase with advancing age, subclinical CVD, such as atherosclerosis, is present for years prior to diagnosis. Thus, the prevention and slowing of CVD progression from middle age to old age are of utmost importance in promoting healthy aging.

There are many reasons why CVD affects older persons at a disproportionate rate. The continuum from risk factor(s) to tissue damage is a simplified albeit important context, for illustrating CVD disease with aging.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Laslett LJ, Alagona P Jr, Clark BA 3rd, et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol. 2012;60:S1–49.

    Article  PubMed  Google Scholar 

  2. Centers for Disease Control and Prevention. Multiple cause of death data, 1999–2012. Centers for Disease Control and Prevention; 2014. Accessed at http://wonder.cdc.gov/mcd.html.

  3. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89–92.

    Article  CAS  PubMed  Google Scholar 

  4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: global burden of disease study. Lancet. 1997;349:1498–504.

    Article  CAS  PubMed  Google Scholar 

  5. Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clin Geriatr Med. 2009;25:563–77, vii.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–603.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310:591–608.

    Article  CAS  PubMed  Google Scholar 

  8. Sniderman AD, Furberg CD. Age as a modifiable risk factor for cardiovascular disease. Lancet. 2008;371:1547–9.

    Article  PubMed  Google Scholar 

  9. den Ouden ME, Schuurmans MJ, Mueller-Schotte S, Bots ML, van der Schouw Y. Do subclinical vascular abnormalities precede impaired physical ability and ADL disability? Exp Gerontol. 2014;58:1–7.

    Article  Google Scholar 

  10. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121:1244–63.

    Article  CAS  PubMed  Google Scholar 

  11. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a “set up” for vascular disease. Circulation. 2003;107:139–46.

    Article  PubMed  Google Scholar 

  12. Dart AM, Kingwell BA. Pulse pressure – a review of mechanisms and clinical relevance. J Am Coll Cardiol. 2001;37:975–84.

    Article  CAS  PubMed  Google Scholar 

  13. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25:932–43.

    Article  CAS  PubMed  Google Scholar 

  14. Paneni F, Diaz Canestro C, Libby P, Luscher TF, Camici GG. The aging cardiovascular system: understanding it at the cellular and clinical levels. J Am Coll Cardiol. 2017;69:1952–67.

    Article  PubMed  Google Scholar 

  15. Barodka VM, Joshi BL, Berkowitz DE, Hogue CW Jr, Nyhan D. Review article: implications of vascular aging. Anesth Analg. 2011;112:1048–60.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Csiszar A, Ungvari Z, Edwards JG, et al. Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ Res. 2002;90:1159–66.

    Article  CAS  PubMed  Google Scholar 

  17. Ungvari Z, Kaley G, de Cabo R, Sonntag WE, Csiszar A. Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci. 2010;65:1028–41.

    Article  PubMed  Google Scholar 

  18. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part II: the aging heart in health: links to heart disease. Circulation. 2003;107:346–54.

    Article  PubMed  Google Scholar 

  19. Shah AM. Ventricular remodeling in heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013;10:341–9.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Cheitlin MD. Cardiovascular physiology-changes with aging. Am J Geriatr Cardiol. 2003;12:9–13.

    Article  PubMed  Google Scholar 

  21. Duncker DJ, Koller A, Merkus D, Canty JM Jr. Regulation of coronary blood flow in health and ischemic heart disease. Prog Cardiovasc Dis. 2015;57:409–22.

    Article  PubMed  Google Scholar 

  22. Ferretti G. Maximal oxygen consumption in healthy humans: theories and facts. Eur J Appl Physiol. 2014;114:2007–36.

    Article  CAS  PubMed  Google Scholar 

  23. Heath GW, Hagberg JM, Ehsani AA, Holloszy JO. A physiological comparison of young and older endurance athletes. J Appl Physiol Respir Environ Exerc Physiol. 1981;51:634–40.

    CAS  PubMed  Google Scholar 

  24. Rogers MA, Hagberg JM, Martin WH 3rd, Ehsani AA, Holloszy JO. Decline in VO2max with aging in master athletes and sedentary men. J Appl Physiol (1985). 1990;68:2195–9.

    Article  CAS  Google Scholar 

  25. Hollenberg M, Yang J, Haight TJ, Tager IB. Longitudinal changes in aerobic capacity: implications for concepts of aging. J Gerontol A Biol Sci Med Sci. 2006;61:851–8.

    Article  PubMed  Google Scholar 

  26. Ribera-Casado JM. Ageing and the cardiovascular system. Z Gerontol Geriatr. 1999;32:412–9.

    Article  CAS  PubMed  Google Scholar 

  27. Fleg JL, Strait J. Age-associated changes in cardiovascular structure and function: a fertile milieu for future disease. Heart Fail Rev. 2012;17:545–54.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ponzetto M, Maero B, Maina P, et al. Risk factors for early and late mortality in hospitalized older patients: the continuing importance of functional status. J Gerontol A Biol Sci Med Sci. 2003;58:1049–54.

    Article  PubMed  Google Scholar 

  29. He S, Craig BA, Xu H, et al. Unmet need for ADL assistance is associated with mortality among older adults with mild disability. J Gerontol A Biol Sci Med Sci. 2015;70:1128–32.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Xu H, Covinsky KE, Stallard E, Thomas J 3rd, Sands LP. Insufficient help for activity of daily living disabilities and risk of all-cause hospitalization. J Am Geriatr Soc. 2012;60:927–33.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Depalma G, Xu H, Covinsky KE, et al. Hospital readmission among older adults who return home with unmet need for ADL disability. Gerontologist. 2013;53:454–61.

    Article  PubMed  Google Scholar 

  32. den Ouden ME, Schuurmans MJ, Mueller-Schotte S, Brand JS, van der Schouw YT. Domains contributing to disability in activities of daily living. J Am Med Dir Assoc. 2013;14:18–24.

    Article  Google Scholar 

  33. den Ouden ME, Schuurmans MJ, Arts IE, van der Schouw YT. Physical performance characteristics related to disability in older persons: a systematic review. Maturitas. 2011;69:208–19.

    Article  Google Scholar 

  34. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305:50–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Wong E, Stevenson C, Backholer K, Woodward M, Shaw JE, Peeters A. Predicting the risk of physical disability in old age using modifiable mid-life risk factors. J Epidemiol Community Health. 2015;69:70–6.

    Article  PubMed  Google Scholar 

  36. Wong E, Tanamas SK, Wolfe R, et al. The role of obesity duration on the association between obesity and risk of physical disability. Obesity (Silver Spring). 2015;23:443–7.

    Article  Google Scholar 

  37. Elbaz A, Shipley MJ, Nabi H, Brunner EJ, Kivimaki M, Singh-Manoux A. Trajectories of the Framingham general cardiovascular risk profile in midlife and poor motor function later in life: the Whitehall II study. Int J Cardiol. 2014;172:96–102.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Rumsfeld JS, Ho PM, Magid DJ, et al. Predictors of health-related quality of life after coronary artery bypass surgery. Ann Thorac Surg. 2004;77:1508–13.

    Article  PubMed  Google Scholar 

  39. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381:752–62.

    Article  PubMed  Google Scholar 

  40. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–56.

    Article  CAS  PubMed  Google Scholar 

  41. Newman AB, Gottdiener JS, McBurnie MA, et al. Associations of subclinical cardiovascular disease with frailty. J Gerontol A Biol Sci Med Sci. 2001;56:M158–66.

    Article  CAS  PubMed  Google Scholar 

  42. Afilalo J, Karunananthan S, Eisenberg MJ, Alexander KP, Bergman H. Role of frailty in patients with cardiovascular disease. Am J Cardiol. 2009;103:1616–21.

    Article  PubMed  Google Scholar 

  43. Veronese N, Cereda E, Stubbs B, et al. Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: results from a meta-analysis and exploratory meta-regression analysis. Ageing Res Rev. 2017;35:63–73.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. Circulation. 2011;123:e18–e209.

    Article  PubMed  Google Scholar 

  45. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366:321–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73–8.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Juutilainen A, Kortelainen S, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care. 2004;27:2898–904.

    Article  PubMed  Google Scholar 

  48. Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57:1542–51.

    Article  PubMed  Google Scholar 

  49. Kappert K, Bohm M, Schmieder R, et al. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Circulation. 2012;126:934–41.

    Article  PubMed  Google Scholar 

  50. Garcia M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular disease in women: clinical perspectives. Circ Res. 2016;118:1273–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Bittner V. Menopause and cardiovascular risk cause or consequence? J Am Coll Cardiol. 2006;47:1984–6.

    Article  PubMed  Google Scholar 

  52. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet. 1998;351:1425–7.

    Article  CAS  PubMed  Google Scholar 

  53. Bairey Merz CN, Shaw LJ, Reis SE, et al. Insights from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol. 2006;47:S21–9.

    Article  PubMed  Google Scholar 

  54. Tremollieres FA, Pouilles JM, Cauneille C, Ribot C. Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis. 1999;142:415–23.

    Article  CAS  PubMed  Google Scholar 

  55. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.

    Article  CAS  PubMed  Google Scholar 

  56. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605–13.

    Article  CAS  PubMed  Google Scholar 

  57. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:3975–4011.

    Article  CAS  PubMed  Google Scholar 

  58. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015–2016. NCHS Data Brief. 2017;(288):1–8.

    Google Scholar 

  59. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53:1925–32.

    Article  PubMed  Google Scholar 

  60. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968–77.

    Article  CAS  PubMed  Google Scholar 

  61. Ne JYA, Cai TY, Celermajer DS, et al. Obesity, arterial function and arterial structure - a systematic review and meta-analysis. Obes Sci Pract. 2017;3:171–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci. 2001;321:225–36.

    Article  CAS  PubMed  Google Scholar 

  63. Twig G, Yaniv G, Levine H, et al. Body-mass index in 2.3 million adolescents and cardiovascular death in adulthood. N Engl J Med. 2016;374:2430–40.

    Article  PubMed  Google Scholar 

  64. Umer A, Kelley GA, Cottrell LE, Giacobbi P Jr, Innes KE, Lilly CL. Childhood obesity and adult cardiovascular disease risk factors: a systematic review with meta-analysis. BMC Public Health. 2017;17:683.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Bowman K, Delgado J, Henley WE, et al. Obesity in older people with and without conditions associated with weight loss: follow-up of 955,000 primary care patients. J Gerontol A Biol Sci Med Sci. 2017;72:203–9.

    Article  PubMed  Google Scholar 

  66. Writing Group Members, Mozaffarian D, Benjamin EJ, et al. Heart disease and stroke Statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–360.

    Google Scholar 

  67. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898–918.

    Article  PubMed  Google Scholar 

  68. Ma C, Avenell A, Bolland M, et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ. 2017;359:j4849.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Yassine HN, Marchetti CM, Krishnan RK, Vrobel TR, Gonzalez F, Kirwan JP. Effects of exercise and caloric restriction on insulin resistance and cardiometabolic risk factors in older obese adults – a randomized clinical trial. J Gerontol A Biol Sci Med Sci. 2009;64:90–5.

    Article  PubMed  CAS  Google Scholar 

  70. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.

    Article  CAS  PubMed  Google Scholar 

  71. Milani RV, Lavie CJ. Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle change with cardiac rehabilitation. Am J Cardiol. 2003;92:50–4.

    Article  PubMed  Google Scholar 

  72. Lavie CJ, Milani RV. Effects of cardiac rehabilitation, exercise training, and weight reduction on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in obese coronary patients. Am J Cardiol. 1997;79:397–401.

    Article  CAS  PubMed  Google Scholar 

  73. Eilat-Adar S, Eldar M, Goldbourt U. Association of intentional changes in body weight with coronary heart disease event rates in overweight subjects who have an additional coronary risk factor. Am J Epidemiol. 2005;161:352–8.

    Article  PubMed  Google Scholar 

  74. Lavie CJ, Milani RV. Obesity and cardiovascular disease: the Hippocrates paradox? J Am Coll Cardiol. 2003;42:677–9.

    Article  PubMed  Google Scholar 

  75. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753–61.

    Article  CAS  PubMed  Google Scholar 

  76. Jamal A, King BA, Neff LJ, Whitmill J, Babb SD, Graffunder CM. Current cigarette smoking among adults – United States, 2005-2015. MMWR Morb Mortal Wkly Rep. 2016;65:1205–11.

    Article  PubMed  Google Scholar 

  77. Rigotti NA, Clair C. Managing tobacco use: the neglected cardiovascular disease risk factor. Eur Heart J. 2013;34:3259–67.

    Article  PubMed  Google Scholar 

  78. Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis. 2003;46:91–111.

    Article  CAS  PubMed  Google Scholar 

  79. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation. 1997;96:3243–7.

    Article  CAS  PubMed  Google Scholar 

  80. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43:1731–7.

    Article  CAS  PubMed  Google Scholar 

  81. Puranik R, Celermajer DS. Smoking and endothelial function. Prog Cardiovasc Dis. 2003;45:443–58.

    Article  CAS  PubMed  Google Scholar 

  82. Burke A, Fitzgerald GA. Oxidative stress and smoking-induced vascular injury. Prog Cardiovasc Dis. 2003;46:79–90.

    Article  CAS  PubMed  Google Scholar 

  83. Aronow WS, Dendinger J, Rokaw SN. Heart rate and carbon monoxide level after smoking high-, low-, and non-nicotine cigarettes. A study in male patients with angina pectoris. Ann Intern Med. 1971;74:697–702.

    Article  CAS  PubMed  Google Scholar 

  84. Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362:2295–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Guirguis-Blake JM, Beil TL, Sun X, Senger CA, Whitlock EP. Primary care screening for abdominal aortic aneurysm: a systematic evidence review for the US Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality; 2014.

    Google Scholar 

  86. Ali MU, Fitzpatrick-Lewis D, Kenny M, Miller J, Raina P, Sherifali D. A systematic review of short-term vs long-term effectiveness of one-time abdominal aortic aneurysm screening in men with ultrasound. J Vasc Surg. 2018;68:612–23.

    Article  PubMed  Google Scholar 

  87. Mons U, Muezzinler A, Gellert C, et al. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ. 2015;350:h1551.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Gellert C, Schottker B, Brenner H. Smoking and all-cause mortality in older people: systematic review and meta-analysis. Arch Intern Med. 2012;172:837–44.

    Article  PubMed  Google Scholar 

  89. Rosenberg L, Kaufman DW, Helmrich SP, Shapiro S. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med. 1985;313:1511–4.

    Article  CAS  PubMed  Google Scholar 

  90. Mortality after 16 years for participants randomized to the multiple risk factor intervention trial. Circulation. 1996;94:946–51.

    Google Scholar 

  91. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233–9.

    Article  PubMed  Google Scholar 

  92. Bakhru A, Erlinger TP. Smoking cessation and cardiovascular disease risk factors: results from the Third National Health and Nutrition Examination Survey. PLoS Med. 2005;2:e160.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290:86–97.

    Article  PubMed  Google Scholar 

  94. Barth J, Jacob T, Daha I, Critchley JA. Psychosocial interventions for smoking cessation in patients with coronary heart disease. Cochrane Database Syst Rev. 2015;(7):CD006886.

    Google Scholar 

  95. Mohiuddin SM, Mooss AN, Hunter CB, Grollmes TL, Cloutier DA, Hilleman DE. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest. 2007;131:446–52.

    Article  PubMed  Google Scholar 

  96. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003;24:946–55.

    Article  CAS  PubMed  Google Scholar 

  97. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121:221–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Ford CL, Zlabek JA. Nicotine replacement therapy and cardiovascular disease. Mayo Clin Proc. 2005;80:652–6.

    Article  CAS  PubMed  Google Scholar 

  99. Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):2176–98.

    Article  PubMed  Google Scholar 

  100. Ikeda N, Sapienza D, Guerrero R, et al. Control of hypertension with medication: a comparative analysis of national surveys in 20 countries. Bull World Health Organ. 2014;92:10–9C.

    Article  PubMed  Google Scholar 

  101. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:2043–50.

    Article  CAS  PubMed  Google Scholar 

  102. Miura K, Daviglus ML, Dyer AR, et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med. 2001;161:1501–8.

    Article  CAS  PubMed  Google Scholar 

  103. Lawes CM, Vander Hoorn S, Rodgers A, International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513–8.

    Article  PubMed  Google Scholar 

  104. Huang Y, Su L, Cai X, et al. Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis. Am Heart J. 2014;167:160–8.e1.

    Article  PubMed  Google Scholar 

  105. Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64:2222–31.

    Article  PubMed  Google Scholar 

  106. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791–8.

    Article  PubMed  Google Scholar 

  107. Yannoutsos A, Levy BI, Safar ME, Slama G, Blacher J. Pathophysiology of hypertension: interactions between macro and microvascular alterations through endothelial dysfunction. J Hypertens. 2014;32:216–24.

    Article  CAS  PubMed  Google Scholar 

  108. Huffman MD, Berry JD, Ning H, et al. Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project. J Am Coll Cardiol. 2013;61:1510–7.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Allen N, Berry JD, Ning H, Van Horn L, Dyer A, Lloyd-Jones DM. Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the cardiovascular lifetime risk pooling project. Circulation. 2012;125:37–44.

    Article  PubMed  Google Scholar 

  110. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–67.

    Article  PubMed  Google Scholar 

  111. SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16.

    Article  CAS  Google Scholar 

  112. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.

    Article  CAS  PubMed  Google Scholar 

  113. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317:165–82.

    Article  PubMed  Google Scholar 

  114. Hajjar I, Lackland DT, Cupples LA, Lipsitz LA. Association between concurrent and remote blood pressure and disability in older adults. Hypertension. 2007;50:1026–32.

    Article  CAS  PubMed  Google Scholar 

  115. Kohler S, Baars MA, Spauwen P, Schievink S, Verhey FR, van Boxtel MJ. Temporal evolution of cognitive changes in incident hypertension: prospective cohort study across the adult age span. Hypertension. 2014;63:245–51.

    Article  PubMed  CAS  Google Scholar 

  116. Hajjar I, Wharton W, Mack WJ, Levey AI, Goldstein FC. Racial disparity in cognitive and functional disability in hypertension and all-cause mortality. Am J Hypertens. 2016;29:185–93.

    Article  PubMed  Google Scholar 

  117. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889–934.

    Article  PubMed  Google Scholar 

  118. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322:1700–7.

    Article  CAS  PubMed  Google Scholar 

  119. Bush TL, Fried LP, Barrett-Connor E. Cholesterol, lipoproteins, and coronary heart disease in women. Clin Chem. 1988;34:B60–70.

    CAS  PubMed  Google Scholar 

  120. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease – the Framingham Heart Study. Can J Cardiol. 1988;4(Suppl A):5A–10A.

    PubMed  Google Scholar 

  121. Krut LH. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1999;281:414; author reply 7-9.

    Article  CAS  PubMed  Google Scholar 

  122. Rubins HB, Robins SJ, Collins D. The veterans affairs high-density lipoprotein intervention trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans affairs cooperative studies program high-density lipoprotein intervention trial study group. Am J Cardiol. 1996;78:572–5.

    Article  CAS  PubMed  Google Scholar 

  123. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–333.

    Article  PubMed  Google Scholar 

  124. Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med. 1993;328:313–8.

    Article  CAS  PubMed  Google Scholar 

  125. Mortensen MB, Falk E. Primary prevention with statins in the elderly. J Am Coll Cardiol. 2018;71:85–94.

    Article  PubMed  Google Scholar 

  126. Jacobson TA, Maki KC, Orringer CE, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9:S1–122.e1.

    Article  PubMed  Google Scholar 

  127. Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1 – full report. J Clin Lipidol. 2015;9:129–69.

    Article  PubMed  Google Scholar 

  128. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.

    Article  CAS  PubMed  Google Scholar 

  129. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152:488–96, W174.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021–31.

    Article  CAS  PubMed  Google Scholar 

  131. Savarese G, Gotto AM Jr, Paolillo S, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2013;62:2090–9.

    Article  CAS  PubMed  Google Scholar 

  132. Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: The ALLHAT-LLT Randomized Clinical Trial. JAMA Intern Med. 2017;177:955–65.

    Article  PubMed  PubMed Central  Google Scholar 

  133. Gurwitz JH, Go AS, Fortmann SP. Statins for primary prevention in older adults: uncertainty and the need for more evidence. JAMA. 2016;316:1971–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2017;40 (Suppl 1):S-135.

    Google Scholar 

  135. Li C, Balluz LS, Okoro CA, et al. Surveillance of certain health behaviors and conditions among states and selected local areas – Behavioral risk factor surveillance system, United States, 2009. MMWR Surveill Summ. 2011;60:1–250.

    PubMed  Google Scholar 

  136. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979;2:120–6.

    Article  CAS  PubMed  Google Scholar 

  137. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med. 1989;320:702–6.

    Article  CAS  PubMed  Google Scholar 

  138. Gerstein HC, Pais P, Pogue J, Yusuf S. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. J Am Coll Cardiol. 1999;33:612–9.

    Article  CAS  PubMed  Google Scholar 

  139. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979;59:8–13.

    Article  CAS  PubMed  Google Scholar 

  140. Schramm TK, Gislason GH, Kober L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008;117:1945–54.

    Article  CAS  PubMed  Google Scholar 

  141. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–607.

    Article  CAS  PubMed  Google Scholar 

  142. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–8.

    Article  PubMed  Google Scholar 

  143. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–16.

    Article  PubMed  Google Scholar 

  144. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119:812–9.

    Article  CAS  PubMed  Google Scholar 

  145. Goldberg RB, Mather K. Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program. Arterioscler Thromb Vasc Biol. 2012;32:2077–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Grant RW, Meigs JB. Should the insulin resistance syndrome be treated in the elderly? Drugs Aging. 2004;21:141–51.

    Article  CAS  PubMed  Google Scholar 

  147. Kim Y, Wilkens LR, Park SY, Goodman MT, Monroe KR, Kolonel LN. Association between various sedentary behaviours and all-cause, cardiovascular disease and cancer mortality: the Multiethnic Cohort Study. Int J Epidemiol. 2013;42:1040–56.

    Article  PubMed  PubMed Central  Google Scholar 

  148. Matthews CE, Chen KY, Freedson PS, et al. Amount of time spent in sedentary behaviors in the United States, 2003-2004. Am J Epidemiol. 2008;167:875–81.

    Article  PubMed  Google Scholar 

  149. Harvey JA, Chastin SF, Skelton DA. How sedentary are older people? A systematic review of the amount of sedentary behavior. J Aging Phys Act. 2015;23:471–87.

    Article  PubMed  Google Scholar 

  150. Endorsed by The Obesity Society, Young DR, Hivert MF, et al. Sedentary behavior and cardiovascular morbidity and mortality: a science advisory from the American Heart Association. Circulation. 2016;134:e262–79.

    Article  Google Scholar 

  151. Grontved A, Hu FB. Television viewing and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a meta-analysis. JAMA. 2011;305:2448–55.

    Article  PubMed  PubMed Central  Google Scholar 

  152. Chomistek AK, Manson JE, Stefanick ML, et al. Relationship of sedentary behavior and physical activity to incident cardiovascular disease: results from the Women’s Health Initiative. J Am Coll Cardiol. 2013;61:2346–54.

    Article  PubMed  PubMed Central  Google Scholar 

  153. Altman R. Risk factors in coronary atherosclerosis athero-inflammation: the meeting point. Thromb J. 2003;1:4.

    Article  PubMed  PubMed Central  Google Scholar 

  154. Fernandez-Friera L, Penalvo JL, Fernandez-Ortiz A, et al. Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation. 2015;131:2104–13.

    Article  PubMed  Google Scholar 

  155. Savji N, Rockman CB, Skolnick AH, et al. Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. J Am Coll Cardiol. 2013;61:1736–43.

    Article  PubMed  Google Scholar 

  156. Walter M. Interrelationships among HDL metabolism, aging, and atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1244–50.

    Article  CAS  PubMed  Google Scholar 

  157. LeFevre ML, U.S. Preventive Services Task Force. Screening for asymptomatic carotid artery stenosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161:356–62.

    Article  PubMed  Google Scholar 

  158. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.

    Article  Google Scholar 

  159. Bibbins-Domingo K, U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164:836–45.

    Article  PubMed  Google Scholar 

  160. Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018;392(10145):387–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  161. McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379(16):1519–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  162. McNeil JJ, Woods RL, Nelson MR, et al. Baseline characteristics of participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study. J Gerontol A Biol Sci Med Sci. 2017;72:1586–93.

    Article  PubMed  PubMed Central  Google Scholar 

  163. McNeil JJ, Woods RL, Nelson MR, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med. 2018;379(16):1499–508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:616–31.

    Article  Google Scholar 

  165. Kuller LH, Shemanski L, Psaty BM, et al. Subclinical disease as an independent risk factor for cardiovascular disease. Circulation. 1995;92:720–6.

    Article  CAS  PubMed  Google Scholar 

  166. Kuller LH, Longstreth WT Jr, Arnold AM, et al. White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke. Stroke. 2004;35:1821–5.

    Article  PubMed  Google Scholar 

  167. Burke GL, Arnold AM, Bild DE, et al. Factors associated with healthy aging: the cardiovascular health study. J Am Geriatr Soc. 2001;49:254–62.

    Article  CAS  PubMed  Google Scholar 

  168. McDermott MM, Ohlmiller SM, Liu K, et al. Gait alterations associated with walking impairment in people with peripheral arterial disease with and without intermittent claudication. J Am Geriatr Soc. 2001;49:747–54.

    Article  CAS  PubMed  Google Scholar 

  169. Longstreth WT Jr, Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke. 1996;27:1274–82.

    Article  PubMed  Google Scholar 

  170. Newman AB, Arnold AM, Naydeck BL, et al. “Successful aging”: effect of subclinical cardiovascular disease. Arch Intern Med. 2003;163:2315–22.

    Article  PubMed  Google Scholar 

  171. Chaves PH, Kuller LH, O’Leary DH, Manolio TA, Newman AB, Cardiovascular Health Study. Subclinical cardiovascular disease in older adults: insights from the Cardiovascular Health Study. Am J Geriatr Cardiol. 2004;13:137–51.

    Article  PubMed  Google Scholar 

  172. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492.

    Article  PubMed  Google Scholar 

  173. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983–8.

    Article  CAS  PubMed  Google Scholar 

  174. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke. 1997;28:316–21.

    Article  CAS  PubMed  Google Scholar 

  175. O’Neal WT, Qureshi WT, Judd SE, et al. Effect of falls on frequency of atrial fibrillation and mortality risk (from the REasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol. 2015;116:1213–8.

    Article  PubMed  PubMed Central  Google Scholar 

  176. Soliman EZ, Safford MM, Muntner P, et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174:107–14.

    Article  PubMed  PubMed Central  Google Scholar 

  177. Chatterjee NA, Chae CU, Kim E, et al. Modifiable risk factors for incident heart failure in atrial fibrillation. JACC Heart Fail. 2017;5:552–60.

    Article  PubMed  PubMed Central  Google Scholar 

  178. Gupta A, Perera T, Ganesan A, et al. Complications of catheter ablation of atrial fibrillation: a systematic review. Circ Arrhythm Electrophysiol. 2013;6:1082–8.

    Article  PubMed  Google Scholar 

  179. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–76.

    Article  PubMed  Google Scholar 

  180. Link MS, Haissaguerre M, Natale A. Ablation of atrial fibrillation: patient selection, periprocedural anticoagulation, techniques, and preventive measures after ablation. Circulation. 2016;134:339–52.

    Article  CAS  PubMed  Google Scholar 

  181. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840–4.

    Article  CAS  PubMed  Google Scholar 

  182. Lau DH, Nattel S, Kalman JM, Sanders P. Modifiable risk factors and atrial fibrillation. Circulation. 2017;136:583–96.

    Article  PubMed  Google Scholar 

  183. Pathak RK, Middeldorp ME, Meredith M, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015;65:2159–69.

    Article  PubMed  Google Scholar 

  184. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.

    Article  PubMed  Google Scholar 

  185. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159:677–85.

    Article  CAS  PubMed  Google Scholar 

  186. Hori M, Connolly SJ, Zhu J, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013;44:1891–6.

    Article  CAS  PubMed  Google Scholar 

  187. Xiong Q, Lau YC, Lip GY. Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation. J Comp Eff Res. 2015;4:367–76.

    Article  PubMed  Google Scholar 

  188. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

    Article  CAS  PubMed  Google Scholar 

  189. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.

    Article  CAS  PubMed  Google Scholar 

  190. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62.

    Article  CAS  PubMed  Google Scholar 

  191. Writing Committee Members, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–327.

    Google Scholar 

  192. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301:383–92.

    Article  CAS  PubMed  Google Scholar 

  193. Ahmed A. Quality and outcomes of heart failure care in older adults: role of multidisciplinary disease-management programs. J Am Geriatr Soc. 2002;50:1590–3.

    Article  PubMed  Google Scholar 

  194. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190–5.

    Article  CAS  PubMed  Google Scholar 

  195. Page RL 2nd, O’Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134:e32–69.

    Article  CAS  PubMed  Google Scholar 

  196. Heckman GA, Shamji AK, Ladha R, et al. Heart failure management in nursing homes: a scoping literature review. Can J Cardiol. 2018;34:871–80.

    Article  PubMed  Google Scholar 

  197. Piepoli MF, Conraads V, Corra U, et al. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail. 2011;13:347–57.

    Article  PubMed  Google Scholar 

  198. Osnabrugge RL, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol. 2013;62:1002–12.

    Article  PubMed  Google Scholar 

  199. Lindman BR, Patel JN. Multimorbidity in older adults with aortic stenosis. Clin Geriatr Med. 2016;32:305–14.

    Article  PubMed  PubMed Central  Google Scholar 

  200. Miller JD, Weiss RM, Heistad DD. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res. 2011;108:1392–412.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  201. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70:252–89.

    Article  PubMed  Google Scholar 

  202. Krane M, Deutsch MA, Piazza N, et al. One-year results of health-related quality of life among patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2012;109:1774–81.

    Article  PubMed  Google Scholar 

  203. Krane M, Deutsch MA, Bleiziffer S, et al. Quality of life among patients undergoing transcatheter aortic valve implantation. Am Heart J. 2010;160:451–7.

    Article  PubMed  Google Scholar 

  204. Georgiadou P, Kontodima P, Sbarouni E, et al. Long-term quality of life improvement after transcatheter aortic valve implantation. Am Heart J. 2011;162:232–7.

    Article  PubMed  Google Scholar 

  205. O’Connor SA, Morice MC, Gilard M, et al. Revisiting sex equality with Transcatheter aortic valve replacement outcomes: a collaborative, patient-level meta-analysis of 11,310 patients. J Am Coll Cardiol. 2015;66:221–8.

    Article  PubMed  Google Scholar 

  206. Zahn R, Werner N, Gerckens U, et al. Five-year follow-up after transcatheter aortic valve implantation for symptomatic aortic stenosis. Heart. 2017;103:1970–6.

    PubMed  Google Scholar 

  207. Bernal E, Ariza-Sole A, Formiga F, et al. Conservative management in very elderly patients with severe aortic stenosis: time to change? J Cardiol. 2017;69:883–7.

    Article  PubMed  Google Scholar 

  208. Gonzalez-Saldivar H, Rodriguez-Pascual C, de la Morena G, et al. Comparison of 1-year outcome in patients with severe aorta stenosis treated conservatively or by aortic valve replacement or by percutaneous Transcatheter aortic valve implantation (data from a Multicenter Spanish Registry). Am J Cardiol. 2016;118:244–50.

    Article  PubMed  Google Scholar 

  209. Afilalo J, Eisenberg MJ, Morin JF, et al. Gait speed as an incremental predictor of mortality and major morbidity in elderly patients undergoing cardiac surgery. J Am Coll Cardiol. 2010;56:1668–76.

    Article  PubMed  Google Scholar 

  210. Green P, Arnold SV, Cohen DJ, et al. Relation of frailty to outcomes after transcatheter aortic valve replacement (from the PARTNER trial). Am J Cardiol. 2015;116:264–9.

    Article  PubMed  PubMed Central  Google Scholar 

  211. Schoenenberger AW, Stortecky S, Neumann S, et al. Predictors of functional decline in elderly patients undergoing transcatheter aortic valve implantation (TAVI). Eur Heart J. 2013;34:684–92.

    Article  CAS  PubMed  Google Scholar 

  212. Arnold SV, Reynolds MR, Lei Y, et al. Predictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER (Placement of Aortic Transcatheter Valve) trial. Circulation. 2014;129:2682–90.

    Article  PubMed  PubMed Central  Google Scholar 

  213. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–607.

    Article  CAS  PubMed  Google Scholar 

  214. Iturra SA, Suri RM, Greason KL, et al. Outcomes of surgical aortic valve replacement in moderate risk patients: implications for determination of equipoise in the transcatheter era. J Thorac Cardiovasc Surg. 2014;147:127–32.

    Article  PubMed  Google Scholar 

  215. Dvir D, Waksman R, Barbash IM, et al. Outcomes of patients with chronic lung disease and severe aortic stenosis treated with transcatheter versus surgical aortic valve replacement or standard therapy: insights from the PARTNER trial (placement of AoRTic TraNscathetER Valve). J Am Coll Cardiol. 2014;63:269–79.

    Article  PubMed  Google Scholar 

  216. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(Suppl S):S5–67.

    Article  PubMed  Google Scholar 

  217. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–24.

    Article  CAS  PubMed  Google Scholar 

  218. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329–40.

    Article  PubMed  Google Scholar 

  219. McDermott MM, Liu K, Greenland P, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA. 2004;292:453–61.

    Article  CAS  PubMed  Google Scholar 

  220. Brach JS, Solomon C, Naydeck BL, et al. Incident physical disability in people with lower extremity peripheral arterial disease: the role of cardiovascular disease. J Am Geriatr Soc. 2008;56:1037–44.

    Article  PubMed  PubMed Central  Google Scholar 

  221. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA. 2001;286:1599–606.

    Article  CAS  PubMed  Google Scholar 

  222. McDermott MM, Ferrucci L, Liu K, et al. Women with peripheral arterial disease experience faster functional decline than men with peripheral arterial disease. J Am Coll Cardiol. 2011;57:707–14.

    Article  PubMed  PubMed Central  Google Scholar 

  223. McDermott MM, Polonsky TS, Kibbe MR, et al. Racial differences in functional decline in peripheral artery disease and associations with socioeconomic status and education. J Vasc Surg. 2017;66:826–34.

    Article  PubMed  PubMed Central  Google Scholar 

  224. Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, et al. Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197–208.

    Article  PubMed Central  Google Scholar 

  225. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90:1314–9.

    Article  CAS  PubMed  Google Scholar 

  226. Olinic DM, Tataru DA, Homorodean C, Spinu M, Olinic M. Antithrombotic treatment in peripheral artery disease. Vasa. 2018;47:99–108.

    Article  PubMed  Google Scholar 

  227. Regensteiner JG, Ware JE Jr, McCarthy WJ, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc. 2002;50:1939–46.

    Article  PubMed  Google Scholar 

  228. Parmenter BJ, Raymond J, Dinnen P, Singh MA. A systematic review of randomized controlled trials: walking versus alternative exercise prescription as treatment for intermittent claudication. Atherosclerosis. 2011;218:1–12.

    Article  CAS  PubMed  Google Scholar 

  229. Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation. 2012;125:130–9.

    Article  PubMed  Google Scholar 

  230. Lane R, Ellis B, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2014;(7):CD000990.

    Google Scholar 

  231. Markel A. Statins and peripheral arterial disease. Int Angiol. 2015;34:416–27.

    CAS  PubMed  Google Scholar 

  232. Writing Committee Members, Gerhard-Herman MD, Gornik HL, et al. 2016 AHA/ACC guideline on the Management of Patients with lower extremity peripheral artery disease: executive summary. Vasc Med. 2017;22:NP1–NP43.

    Article  Google Scholar 

  233. Nehler MR, Duval S, Diao L, et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J Vasc Surg. 2014;60:686–95.e2.

    Article  PubMed  Google Scholar 

  234. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463–654.

    Article  PubMed  Google Scholar 

  235. Jones WS, Patel MR, Dai D, et al. High mortality risks after major lower extremity amputation in Medicare patients with peripheral artery disease. Am Heart J. 2013;165:809–15, 815.e1.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rebecca S. Boxer .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Reynolds, I., Page, R.L., Boxer, R.S. (2019). Cardiovascular Health and Healthy Aging. In: Coll, P. (eds) Healthy Aging. Springer, Cham. https://doi.org/10.1007/978-3-030-06200-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-06200-2_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-06199-9

  • Online ISBN: 978-3-030-06200-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics